Elekta
77 SEK -2.78%8 investors are following this company
Elekta provides medical technology. The company specializes in the development of clinical solutions for the treatment of cancer and brain diseases. Elekta's treatment system and planning software for radiation therapy and radiation surgery as well as other software systems are used in the healthcare industry to identify and analyze various health conditions. Operations are conducted on a global level, with headquarters in Stockholm.
Revenue
16.87B
EBIT %
8.48 %
P/E
31.17
Dividend yield-%
3.12 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
EKTA B
Daily low / high price
77 / 79.2
SEK
Market cap
29.53B SEK
Turnover
73.39M SEK
Volume
949K
Financial calendar
Annual report
2024-06-05
General meeting
2024-09-05
Interim report
2024-09-05
Interim report
2024-11-27
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fjärde AP-fonden | 9.2 % | 6.8 % |
Laurent Leksell fam och bolag | 5.7 % | 30.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Elekta and GE HealthCare’s MIM Software enter significant collaboration to deliver leading cancer treatment planning solutions
Invitation to investor meeting at ESTRO 2024 in Glasgow
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools